| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable …
Over the last 12 months, insiders at Acurx Pharmaceuticals, Inc. have bought $0 and sold $0 worth of Acurx Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Acurx Pharmaceuticals, Inc. have bought $122,306 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 49,261 shares for transaction amount of $50,000 was made by LUCI DAVID P (President and CEO) on 2025‑01‑06.
| 2025-01-06 | LUCI DAVID P | President and CEO | 49,261 0.2642% | $1.01 | $50,000 | -67.22% | ||
| 2025-01-06 | DELUCCIA ROBERT J | 49,261 0.2642% | $1.01 | $50,000 | -67.22% | |||
| 2025-01-06 | Sailer Carl | director | 24,631 0.1321% | $1.01 | $25,000 | -67.22% | ||
| 2025-01-06 | Scodari Joseph C | director | 24,631 0.1321% | $1.01 | $25,000 | -67.22% | ||
| 2025-01-06 | Donohue James J. | director | 9,852 0.0528% | $1.01 | $10,000 | -67.22% | ||
| 2025-01-06 | DEAN JACK H | director | 9,852 0.0528% | $1.01 | $10,000 | -67.22% | ||
| 2021-11-23 | Sailer Carl | director | 5,161 0.0628% | $4.84 | $24,979 | -21.67% | ||
| 2021-11-19 | DELUCCIA ROBERT J | 5,034 0.0595% | $4.90 | $24,672 | -24.69% | |||
| 2021-11-19 | LUCI DAVID P | President and CEO | 5,200 0.0602% | $4.80 | $24,960 | -24.69% | ||
| 2021-06-29 | Sailer Carl | director | 12,500 0.1719% | $6.00 | $75,000 | -30.67% |
| LUCI DAVID P | President and CEO | 1097458 19.7406% | $1.12M | 2 | 0 | |
| DELUCCIA ROBERT J | 1010196 18.1709% | $1.03M | 2 | 0 | ||
| Sailer Carl | director | 137183 2.4676% | $139,926.66 | 3 | 0 | <0.0001% |
| Scodari Joseph C | director | 27708 0.4984% | $28,262.16 | 1 | 0 | |
| Donohue James J. | director | 22352 0.4021% | $22,799.04 | 1 | 0 | |
| DEAN JACK H | director | 21776 0.3917% | $22,211.52 | 1 | 0 |
$6,974,678 | 45 | -14.98% | $4.63M | |
$13,664,154 | 40 | -70.35% | $7.05M | |
$29,645,465 | 28 | 8.09% | $6.48M | |
$63,749,694 | 24 | -12.24% | $6.4M | |
$287,718 | 15 | -41.45% | $5.68M |
| Increased Positions | 10 | +40% | 110,348 | +173.35% |
| Decreased Positions | 11 | -44% | 35,388 | -55.59% |
| New Positions | 7 | New | 107,250 | New |
| Sold Out Positions | 5 | Sold Out | 26,819 | Sold Out |
| Total Postitions | 24 | -4% | 138,617 | +117.76% |
| Prospect Financial Services Llc | $55.00 | 0.99% | 19,883 | +5,044 | +33.99% | 2025-09-30 |
| Susquehanna International Group, Llp | $46.00 | 0.84% | 16,815 | +13,328 | +382.22% | 2025-09-30 |
| Sabby Management, Llc | $24.00 | 0.44% | 8,705 | +4,610 | +112.58% | 2025-09-30 |
| Osaic Holdings, Inc. | $22.00 | 0.39% | 7,824 | +7,301 | +1,395.98% | 2025-09-30 |
| Morgan Stanley | $15.00 | 0.27% | 5,310 | 0 | 0% | 2025-09-30 |
| Nbc Securities, Inc. | $4.00 | 0.08% | 1,500 | 0 | 0% | 2025-09-30 |
| Gps Wealth Strategies Group, Llc | $3.00 | 0.06% | 1,225 | +50 | +4.25% | 2025-09-30 |
| Tower Research Capital Llc (Trc) | $3.00 | 0.05% | 1,077 | +869 | +417.79% | 2025-09-30 |
| Citigroup Inc | $1.00 | 0.02% | 453 | +453 | New | 2025-09-30 |
| Group One Trading Llc | $1.00 | 0.02% | 298 | -382 | -56.18% | 2025-09-30 |